Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-tumoural concentration and activity of nilotinib in intra-cutaneous schwannomas
2010-023508-28Phase 4Terminated
- Sponsor
- University Hospitals Plymouth
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nilotinib in neurofibromatosis type 2 (NF2) and schwannoma, sponsored by University Hospitals Plymouth. Primary endpoints: Molecular target inhibition in cutaneous schwannomas, Steady-state plasma concentration of nilotinib and 1 more. Started Nov 2010; status: terminated.
02
Drugs
nilotinib
03
Conditions
neurofibromatosis type 2 (NF2)schwannoma
Beyond the preview
Go deeper on 2010-023508-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023508-28.